Navigation Links
Vista Partners Initiates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx)
Date:3/18/2008

LOS ANGELES, March 18 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on leading Australian biotechnology company Arana Therapeutics, (ASX: AAH; AIM: AAHx). "Cash on hand and royalty revenue alone are equal to roughly US$0.94 in share value. Add to that our US$0.43 probability weighted, DCF value for ART621 and you have a premium of nearly 70% to the current market price. This comes without assigning any value to their current pre-clinical pipeline which we feel has great potential," said Ross Silver, Director of Research for Vista Partners. For more information and to download the free report, please visit the Vista Partners website at http://www.vistap.com.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Arana Therapeutics:

Arana Therapeutics (ASX: AAH; AIM: AAHx) is an international biopharmaceutical company formed through the merger of Peptech and EvoGenix in August 2007. The company uses superior technology to develop next generation drugs that will improve the lives of patients with inflammatory diseases and cancer. Arana Therapeutics' innovative engineering technologies provide the basis for clinical development in the antibody space, a market which draws on high demand. Arana Therapeutics has the financial stability and management expertise to accelerate its clinical programs, and is on track to have at least 3 clinical stage assets within three years. Arana is listed on the Australian Securities Exchange (ASX) and the London Stock Exchange (AIM). The pipeline consists of four lead drug programs: ART621 to treat severe rheumatoid arthritis, psoriasis and other inflammatory diseases; ART010 to treat osteoporosis and bone cancer; ART104 to treat solid tumours in colorectal cancer; and ART150 for lung cancer and melanoma. Additionally, the company has earlier stage products in development for the treatment of a range of conditions including age related macular degeneration, psoriasis, colorectal cancer, and leukemia. Arana has recurring revenues from commercial and development partnerships with six international companies including GSK, CSL, Centocor (J&J) and Abbott Laboratories.

Contact:

Vista Partners LLC

Ross Silver

(310) 744-5268

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
2. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
10. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
11. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 11, 2016 , ... Registered nurses, licensed practical nurses and nursing aides who ... to Act, Time to Heal” on Thursday, February 25 from 9:00 to 11:00 a.m. ... Vishal Chedda, president of ANSA Consultants, who will discuss clinical best practices throughout the ...
(Date:2/11/2016)... ... , ... Image One USA veteran franchise owner Maria Bogacki is ... of Nashville that will benefit. , “I’ve enjoyed being a part of the Image ... no question that I would bring my business with me,” Bogacki said. “The entire ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric ... to improve care by making data on heart procedures public and easily understandable ... Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes will bring ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS ... support technology, with highly adaptable algorithms, has been updated to help Emergency Department ... and symptoms consistent with Zikas and a travel history to affected regions, or ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for ... men, 60 and older, who gather once a year to play softball to raise ... for the game, the more than 50 players who competed in this year’s softball ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 --> --> ... research report, titled "Sports Medicine Devices Market - Global Industry ... According to the report, the global sports medicine devices market ... to 2019, growing from a value of US$6.1 bn in ... --> The global sports medicine devices market ...
(Date:2/11/2016)... , February 11, 2016 F ... answers at the ... a world-leading provider of scientific, technical and medical information products and services, ... to evidence-based, peer reviewed clinical information via a mobile device. Elsevier designed ... ClinicalKey for Nursing. The new app is available in Android ...
(Date:2/11/2016)... 11, 2016  M3 Biotechnology Inc., spurred by a major "team investment" by Bruce Montgomery ... completed an oversubscribed Series A-Round, according to CEO Leen Kawas , PhD. ... ... ... Kawas said ...
Breaking Medicine Technology: